Oncology Medical News about non-small cell lung cancer;chromosomal region 5p15.33

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer
Cancer Genetics and Cytogenetics, 03/12/08

Kang JU et al. - In a trial to identify early-stage genetic events that drive progression of non-small cell lung cancer (NSCLC), it was shown that the gain of 5p15.33 is one of the most consistent alterations in the early stages of lung cancer, and a series of genes in the critical 5p15.33 region may be used as novel biomarkers for early detection and classification of lung cancer

Methods

A high-resolution array comparative genomic hybridization (CGH) study was done using an array of 4046 bacterial artificial chromosome clones to screen for DNA copy number changes associated with individual genes in 36 tumors from pts in early stages of NSCLC

Results

Multiple early genetic events occurring on chromosome 5p were identified, with a minimal detection region at 5p15.33 at approximately 12
The most frequent finding involved gain of 5p15.33, observed in 15 of 19 stage I (A+B) cancers and in 28 of 36 NSCLC cases
This locus harbors the genes TERT, SLC6A19, and SLC6A18 and is a telomeric boundary at bacterial artificial chromosome (BAC) clone 91_J20
Other potential candidate genes evidencing high numbers of genomic copy number changes included the following genes, encountered in >50% of 19 stage I (A+B) cancers: CEP72 and TPPP; AHRR, EXOC3, SLC9A3, LOC442126, ZDHHC11, BRD9, and TRIP13; and CLPTM1L, SLC6A3, and LOC401169
Fluorescence in situ hybridization validated the array CGH findings

<< Previous
Recommendations on the use of 18F-FDG PET in oncology

Next >>
Diagnosis and management of neoplastic lesions of the...